InvestmentJun 4, 2026, 08:01 AM
Imunon Secures $10M Financing for Phase 3 Ovarian Cancer Trial
AI Summary
Imunon, Inc. announced it has secured $10 million in financing to support the continued enrollment of its pivotal Phase 3 OVATION 3 clinical trial for IMNN-001 in advanced ovarian cancer. The financing package includes $2.5 million from the issuance of preferred stock and $7.72 million from two secured promissory notes. The company highlighted this "investor-friendly" structure as designed to minimize dilution for existing shareholders and strengthen its balance sheet, while also referencing positive updated Phase 2 clinical data for IMNN-001.
Key Highlights
- Secured $10 million in aggregate gross proceeds through a structured financing.
- Financing includes $2.5 million from 250 shares of non-redeemable, non-convertible preferred stock.
- Includes two secured promissory notes totaling $7.72 million.
- Promissory notes carry interest rates of 8% and 5% per annum, maturing in 18 months.
- Proceeds will fund continued enrollment in the pivotal Phase 3 OVATION 3 study.
- Updated Phase 2 data showed median overall survival increased by 14.7 months.
- Patients on PARP inhibitors showed a 24.2-month increase in median overall survival.
Price Impact
More from IMNN